Lunit Launches Enhanced Lunit INSIGHT CXR4, Secures CE MDR Certification for Expanded AI Capabilities
Next-generation AI solution introduces new clinical features and broader disease detection for chest X-rays
SEOUL, South Korea, May 28, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and therapeutics, today announced the official launch and CE certification under the Medical Device Regulation (MDR) of Lunit INSIGHT CXR4, its next-generation chest X-ray analysis solution.
Lunit INSIGHT CXR4 is a comprehensive AI solution for chest imaging, designed to support radiologists across a wide range of clinical scenarios. It leverages advanced AI to detect 12 types of chest abnormalities—including lung nodules, pneumonia, and pneumothorax—expanding its diagnostic capabilities to include additional findings such as acute bone fractures. Trained on large-scale real-world datasets, the upgraded solution delivers improved diagnostic accuracy while supporting early detection of critical diseases.
In addition to expanded disease detection, Lunit INSIGHT CXR4 introduces several new features designed to enhance clinical workflow and diagnostic support:
With CE MDR certification, Lunit is now positioned to deploy INSIGHT CXR4 across Europe—offering enhanced diagnostic confidence and workflow efficiency for radiologists managing high imaging volumes.
"With Lunit INSIGHT CXR4, we've gone beyond expanding detection—we've focused on what truly helps clinicians in their day-to-day workflow," said Brandon Suh, CEO of Lunit. "Features like active normal flagging and current-prior comparison are designed to reduce reading time and improve triage confidence, especially in high-volume settings. CE MDR certification is a key step toward broader adoption, and we're committed to bringing CXR4 to more hospitals worldwide."
With CE MDR certification now in place, Lunit is preparing to pursue additional regulatory approvals to make CXR4 available in more regions. The company aims to further integrate its AI solutions into clinical workflows across diverse healthcare systems.
CE MDR is the EU's enhanced regulatory standard for medical devices, ensuring stricter standards for safety, performance, and clinical validation.
About Lunit
Founded in 2013, Lunit (KRX:328130.KQ) is a global leader in AI for cancer diagnostics and therapeutics. With a mission to conquer cancer through AI, Lunit develops AI-powered solutions for medical imaging and biomarker analysis to enable precise diagnosis and personalized treatment. Lunit's FDA-cleared Lunit INSIGHT suite supports cancer screening at over 4,800 medical institutions in more than 55 countries. Lunit clinical studies have been featured in top-tier journals—including The Lancet Digital Health and Journal of Clinical Oncology —and presented at major conferences such as ASCO and RSNA. Headquartered in Seoul with global offices, Lunit is driving the worldwide fight against cancer. Learn more at lunit.io.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
13 hours ago
- Korea Herald
China to Host Global Tech Visionaries at GSMA MWC25 Shanghai: Asia Pacific's Flagship Mobile Tech Event Reveals Speaker Lineup and Programme Highlights
LONDON, June 6, 2025 /PRNewswire/ -- GSMA MWC25 Shanghai promises to be a defining moment for Asia Pacific's technology market as innovators, policymakers and business leaders from around the world get ready to converge at the Shanghai New International Expo Centre (SNIEC) and Kerry Hotel Pudong, on 18-20 June 2025. With China cementing its status as a global powerhouse of mobile technology – and the world's largest 5G market – MWC25 Shanghai will explore how 5G, AI, and IoT are transforming industries and accelerating a new era of intelligent, connected growth. MWC Shanghai brings together global operators, vendors, solutions-providers and the Chinese connectivity ecosystem. Mobile connectivity is projected to contribute $2 trillion to China's economy and nearly $11 trillion to global GDP by 2030, advancing productivity and enabling smarter and more sustainable societies. These themes will be front and centre at MWC25 Shanghai, which will gather some of the most influential technology and business voices in Asia Pacific. Confirmed keynote speakers include: New and Highlighted Features at MWC25 Shanghai include: GSMA Policy Leaders Forum: Coming to MWC Shanghai for the first time, the PLF is an exclusive forum where global policymakers and industry leaders will gather to discuss policy and regulation. Topics will include the impact and opportunities of AI, closing the digital divide, as well as mobile and AI's convergence and its future potential towards 6G. In addition, discussions will include factors that enabled China's rapid evolution to 5G-Advanced and digital connectivity and, the digital transformation incentives needed for the growth of digital nations.
Korea Herald
14 hours ago
- Korea Herald
Haier's Strategic Partnership with Roland-Garros Enters Third Year, Driving Shared Values of Excellence
PARIS, June 6, 2025 /PRNewswire/ -- As the 2025 Roland-Garros (French Open) enters its final stretch, the iconic clay courts of Paris are once again alive with the intensity and elegance that define the Grand Slam. At the heart of this prestigious tournament, Haier celebrates the third year of its strategic partnership with Roland-Garros, first launched in 2023. This enduring collaboration reflects a shared commitment to excellence, innovation, and resilience, values that resonate both on the court and across Haier's global vision for premium living. Forging Strength and Grace: A Shared Journey of Excellence While every Grand Slam tournament tests a player's determination and skill, Roland-Garros stands apart for its demand for finesse, resilience, and endurance on clay. Similarly, Haier's journey in building a global brand began in 1990 and it took 25 years of unwavering commitment to achieve financial self-balance in overseas markets, reflecting the endurance and long-term vision that define both sport and business. Beyond endurance, Roland-Garros stands as a beacon of global prestige and refined standards, while Haier has cultivated a reputation as a leading high-end brand in Europe. Together, they embody a powerful synergy of perseverance and sophistication on the global stage. As global momentum toward intelligent and sustainable innovation accelerates, the 2025 AI Action Summit in Paris exemplifies a shared international ambition for inclusive, energy-efficient, and human-centered technology. In this context, Haier continues to lead the way. In France, Haier's Langjing X11 washing machine exemplified its commitment, delivering 60% energy savings compared to Europe's rigorous A-class standards—a critical advantage amid rising energy concerns. With premium pricing (reflected in a price index of 275 in Poland and 375 in the UK), the Langjing X11 reinforces Haier's innovative, high-end positioning. In 2024, Haier achieved 47% brand awareness in France, highlighting its growing influence among discerning consumers. Strategic Expansion of Haier in Europe: Deep Roots and Localized Excellence The success of Haier in France is the result of a long-term commitment to deep localization and strategic expansion across Europe. Since entering Germany in the 1990s, Haier has built a strong and steady presence across the continent, driven by a consistent focus on innovation and user needs. At the core of the European growth of Haier is the 3-in-1 strategy (localized R&D, manufacturing, and marketing), enabling the brand to respond quickly and effectively to local demand. For instance, in the European market where air conditioner penetration remains below 5%, Haier introduced a smart air solution with simplified installation to meet local needs with precision and efficiency. The spirit of persistence and dedication to innovation, grounded in a deep understanding of local markets, has propelled the steady rise of Haier across multiple European countries. Haier continues to lead in Europe. This success story reflects the ongoing dedication of Haier to innovation and localization, anchored by the 3-in-1 strategy, which continues to drive its strong market presence and recognition, with brand awareness reaching approximately 30% across Europe in 2024. Haier ESG Commitment: Empowering a Greener, More Inclusive Future The partnership between Haier and Roland-Garros goes beyond the court and represents a shared commitment to promoting healthy lifestyles, advancing social responsibility, and creating sustainable value for communities across the globe. At Roland-Garros, Haier brought its ESG values to life through an immersive pop-up experience, showcasing its latest advancements in sustainable technology. Demonstrating a firm commitment to nurturing the next generation, Haier partnered with Open Stade Français to launch the "Haier Fans Cup", offering young winners the unique opportunity to attend the tournament and meet former WTA Number one champion Ana Ivanovic. Further reflecting its people-centric and innovation-driven approach, Haier France was awarded the Gold certification for Great Onboarding from Workelo, demonstrating its dedication to building a future-ready workplace. From homes to communities, from sustainable technologies to human-centered governance, Haier is setting a new standard for global brands.
Korea Herald
14 hours ago
- Korea Herald
HTL Biotechnology inaugurates a new production line dedicated to sterile hyaluronic acid
JAVENÉ, France, June 6, 2025 /PRNewswire/ -- On the occasion of National Bioproduction and Biomedicines Day (JNBB), which enjoys the high patronage of the President of the French Republic, HTL Biotechnology confirms its position as a globalleader in the development and production of pharmaceutical-grade biopolymers, by inaugurating a new production unit dedicated to sterile hyaluronic acid at its Javené (Ille-et-Vilaine) site, a true flagship of French biomanufacturing. With over 30 years of expertise in biopolymers, HTL Biotechnology is reaffirming its commitment through this new production unit to the development of innovative therapeutic solutions for the medicine of today and tomorrow. The manufacture of sterile hyaluronic acid opens the way to new therapeutic opportunites . This cutting-edge process now makes it possible to combine hyaluronic acid with heat-sensitive active molecules, previously incompatible with traditional heat sterilization methods. Simultaneously, mastery of aseptic processes eliminates any risk of microbial contamination and ensures optimum pharmaceutical quality. This innovation marks a decisive step in the development of new combined formulations, bringing improved clinical benefits for patients in many fields, such as ophthalmology and drug delivery. This €12 million investment, part of HTL Biotechnology's €100 million 2022-2026 strategic plan, pursues two main goals: to explore new opportunities in bioproduction, and to strengthen the company's position as a key player in future applications of hyaluronic acid in healthcare. Production is scheduled to start in 2026, following qualification and validation of the industrial equipment. To guarantee the quality and efficiency of this new production unit, HTL Biotechnology has set up specific in-house training courses to instruct its staff in aseptic procedures and the handling of this new product. Because of the highly technical nature of this product, a team of ten specialists has been trained in the specific skills required for its production ensuring the highest quality standards. François Fournier, CEO of HTL Biotechnology, states: " I'm delighted with the prospects this investment gives us for further innovation in pharmaceutical-grade biopolymers. The breadth and complementarity of our portfolio is unique, and we are proud to be able to serve our customers even better. Thanks to this new unit, promising future applications can be explored, offering innovative solutions for the benefit of patients. I am delighted to be able to count on this new facility, which makes our historic Javené site a true flagship for French bioproduction." As an active member of France Biolead, HTL Biotechnology is proud to take part in the second National Biomanufacturing and Biomedicines Day, which this year enjoys the patronage of French President Emmanuel Macron. The company welcomes this recognition, which underscores the strategic importance of the French biomanufacturing and biomedical industry, at the heart of the challenges facing public health, and France. About HTL HTL Biotechnology is a French biotech company and world leader in the development and responsible biomanufacturing of pharmaceutical-grade biopolymers (Hyaluronic Acid, Polynucleotides and soon recombinant human collagen). These biopolymers are used by healthcare companies to develop treatments in a variety of leading therapeutic areas such as ophthalmology, dermatology, medical aesthetics and rheumatology. HTL Biotechnology recently strengthened its position as world leader in the development of pharmaceutical-grade biopolymers by acquiring, through its subsidiary HTL Biotechnology Innovation Inc. (HTL BII - New Jersey), a recombinant protein platform whose most advanced product is recombinant human collagen type III (rhCOL3) at a world-class scientific research center. To meet the world's growing need for biopolymers, the company also has subsidiaries in Asia and is building a neuromodulator production unit in the United States (HTL BMI - Massachusetts). Historically based in Javené (Brittany - France), the company brings together production, innovation, R&D , as well as quality activities on its site. HTL Biotechnology employs nearly 300 people worldwide. Press contact
